401 related articles for article (PubMed ID: 20001804)
1. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.
Gurova K
Future Oncol; 2009 Dec; 5(10):1685-704. PubMed ID: 20001804
[TBL] [Abstract][Full Text] [Related]
2. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology.
Cheung-Ong K; Giaever G; Nislow C
Chem Biol; 2013 May; 20(5):648-59. PubMed ID: 23706631
[TBL] [Abstract][Full Text] [Related]
3. The modulation of the DNA-damaging effect of polycyclic aromatic agents by xanthines. Part I. Reduction of cytostatic effects of quinacrine mustard by caffeine.
Kapuscinski J; Ardelt B; Piosik J; Zdunek M; Darzynkiewicz Z
Biochem Pharmacol; 2002 Feb; 63(4):625-34. PubMed ID: 11992630
[TBL] [Abstract][Full Text] [Related]
4. Methods for Elucidation of DNA-Anticancer Drug Interactions and their Applications in the Development of New Drugs.
Misiak M; Mantegazza F; Beretta GL
Curr Pharm Des; 2016; 22(44):6596-6611. PubMed ID: 27587197
[TBL] [Abstract][Full Text] [Related]
5. Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs.
Nesher E; Safina A; Aljahdali I; Portwood S; Wang ES; Koman I; Wang J; Gurova KV
Cancer Res; 2018 Mar; 78(6):1431-1443. PubMed ID: 29339544
[TBL] [Abstract][Full Text] [Related]
6. The potential of combi-molecules with DNA-damaging function as anticancer agents.
Sun G; Fan T; Zhao L; Zhou Y; Zhong R
Future Med Chem; 2017 Mar; 9(4):403-435. PubMed ID: 28263086
[TBL] [Abstract][Full Text] [Related]
7. Amplification of anticancer drug-induced DNA damage and apoptosis by DNA-binding compounds.
Kawanishi S; Hiraku Y
Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):415-9. PubMed ID: 15379695
[TBL] [Abstract][Full Text] [Related]
8. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
Mitsiades N; Poulaki V; Mitsiades CS; Anderson KC
Expert Opin Investig Drugs; 2001 Jun; 10(6):1075-84. PubMed ID: 11772236
[TBL] [Abstract][Full Text] [Related]
9. Preferential targeting of apoptosis in tumor versus normal cells.
Woynarowska BA; Woynarowski JM
Biochim Biophys Acta; 2002 Jul; 1587(2-3):309-17. PubMed ID: 12084473
[TBL] [Abstract][Full Text] [Related]
10. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances.
Kizek R; Adam V; Hrabeta J; Eckschlager T; Smutny S; Burda JV; Frei E; Stiborova M
Pharmacol Ther; 2012 Jan; 133(1):26-39. PubMed ID: 21839775
[TBL] [Abstract][Full Text] [Related]
11. DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.
Holden JA
Curr Med Chem Anticancer Agents; 2001 May; 1(1):1-25. PubMed ID: 12678768
[TBL] [Abstract][Full Text] [Related]
12. Chromatin Stability as a Target for Cancer Treatment.
Gurova KV
Bioessays; 2019 Jan; 41(1):e1800141. PubMed ID: 30566250
[TBL] [Abstract][Full Text] [Related]
13. DNA Damaging Agents in Chemical Biology and Cancer.
Sauter B; Gillingham D
Chimia (Aarau); 2020 Sep; 74(9):693-698. PubMed ID: 32958106
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy.
Vecchio D; Frosina G
Curr Drug Targets; 2016; 17(2):139-53. PubMed ID: 25382204
[TBL] [Abstract][Full Text] [Related]
15. Designed enediynes: a new class of DNA-cleaving molecules with potent and selective anticancer activity.
Nicolaou KC; Dai WM; Tsay SC; Estevez VA; Wrasidlo W
Science; 1992 May; 256(5060):1172-8. PubMed ID: 1589797
[TBL] [Abstract][Full Text] [Related]
16. Damage to DNA strand and the effects of anticancer drugs.
Kanamaru R; Ishioka C; Konishi Y; Ishikawa A; Shibata H; Wakui A
Sci Rep Res Inst Tohoku Univ Med; 1989 Dec; 36(1-4):29-36. PubMed ID: 2640065
[TBL] [Abstract][Full Text] [Related]
17. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter.
Sohn TA; Bansal R; Su GH; Murphy KM; Kern SE
Carcinogenesis; 2002 Jun; 23(6):949-57. PubMed ID: 12082016
[TBL] [Abstract][Full Text] [Related]
18. Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents.
Nekkanti S; Tokala R; Shankaraiah N
Curr Med Chem; 2017; 24(26):2887-2907. PubMed ID: 28545367
[TBL] [Abstract][Full Text] [Related]
19. Death receptor ligands, in particular TRAIL, to overcome drug resistance.
de Jong S; Timmer T; Heijenbrok FJ; de Vries EG
Cancer Metastasis Rev; 2001; 20(1-2):51-6. PubMed ID: 11831647
[TBL] [Abstract][Full Text] [Related]
20. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
